Window of Opportunity Trial of Nivolumab and Tadalafil in Patients With Squamous Cell Carcinoma of the Head and Neck
Status: Active, no longer recruiting
Phase of Trial: Phase 0
Latest Information Update: 15 Jul 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary) ; Tadalafil (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Pharmacodynamics
- 11 Jul 2019 Status changed from recruiting to active, no longer recruiting.
- 04 Jun 2019 Results determining the frequency of discordant treatment effects in HNSCC patients treated with immunotherapy in the context of a neoadjuvant trial presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 18 Sep 2017 Status changed from not yet recruiting to recruiting.